Citigroup’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $364K | Sell |
18,139
-12,700
| -41% | -$255K | ﹤0.01% | 3092 |
|
|
2025
Q1 | $607K | Sell |
30,839
-2,709
| -8% | -$53.3K | ﹤0.01% | 2847 |
|
|
2024
Q4 | $755K | Buy |
33,548
+4,650
| +16% | +$105K | ﹤0.01% | 2775 |
|
|
2024
Q3 | $738K | Buy |
28,898
+18,296
| +173% | +$467K | ﹤0.01% | 2763 |
|
|
2024
Q2 | $248K | Buy |
10,602
+2,769
| +35% | +$64.7K | ﹤0.01% | 3070 |
|
|
2024
Q1 | $138K | Buy |
7,833
+427
| +6% | +$7.51K | ﹤0.01% | 3430 |
|
|
2023
Q4 | $102K | Buy |
7,406
+4,059
| +121% | +$56.2K | ﹤0.01% | 3450 |
|
|
2023
Q3 | $45.7K | Sell |
3,347
-7,476
| -69% | -$102K | ﹤0.01% | 3483 |
|
|
2023
Q2 | $221K | Sell |
10,823
-440
| -4% | -$8.98K | ﹤0.01% | 3186 |
|
|
2023
Q1 | $247K | Buy |
+11,263
| New | +$247K | ﹤0.01% | 2993 |
|
|
2021
Q2 | – | Sell |
-127
| Closed | -$4K | – | 5475 |
|
|
2021
Q1 | $4K | Sell |
127
-227
| -64% | -$7.15K | ﹤0.01% | 5267 |
|
|
2020
Q4 | $31K | Buy |
354
+294
| +490% | +$25.7K | ﹤0.01% | 4377 |
|
|
2020
Q3 | $5K | Sell |
60
-108
| -64% | -$9K | ﹤0.01% | 4641 |
|
|
2020
Q2 | $19K | Buy |
+168
| New | +$19K | ﹤0.01% | 4281 |
|